Synthesis of phenyl (6-(2-fluoro-4-nitrophenoxy)pyrimidin-4-yl)carbamate

doi:10.1063/5.0048683

Paper

Synthesis of phenyl (6-(2-fluoro-4-nitrophenoxy)pyrimidin-4-yl)carbamate

Published Apr 27, 2021 · Wenhui Gan, Jinjin Wu, Hualan Zhou

UNKNOWN SJR score

0

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Phenyl (6-(2-fluoro-4-nitrophenoxy)pyrimidin-4-yl)carbamate (7) was an important intermediate of many antitumor drugs, especially, it is widely used in small molecular inhibitors of anti-tumor. Compound 7 was synthesized from 6-chloropyrimidine-4-amine by acylation and nucleophilic substitution. The structures of the intermediates were confirmed by MS and 1H NMR. Furthermore, the synthetic method was optimized.

Study Snapshot

Phenyl (6-(2-fluoro-4-nitrophenoxy)pyrimidin-4-yl)carbamate (7) is an important intermediate in antitumor drugs, and its synthetic method has been optimized for efficient production.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Synthesis of phenyl (6-(2-fluoro-4-nitrophenoxy)pyrimidin-4-yl)carbamate

Sign up to use Study Snapshot

References

Selective Defluoroallylation of Trifluoromethylarenes.

This study presents a fluoride-initiated coupling reaction between trifluoromethylarenes and allylsilanes for efficient and selective access to allylated,-difluorobenzylic compounds.

Cardiorespiratory fitness, physical activity and cancer mortality in men.

Moderate and high cardiorespiratory fitness levels and meeting minimal physical activity guidelines have protective benefits against cancer mortality in men.

A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway

968 effectively inhibits non-small cell lung cancer cell proliferation and migration, offering a new therapeutic strategy for lung cancer treatment when combined with autophagy inhibitor Chloroquine.

Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.

Small-molecule EGFR inhibitors show promise in treating non-small-cell lung cancer by targeting T790M resistance mutations while sparing the wild-type form of the receptor.

EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.

CD82 down-regulation is a critical step in EGFR over-expression and stronger tumorigenic activity in lung cancers harboring EGFR mutations, suggesting that up-regulating CD82 levels may be a promising new treatment strategy.

Citations